Human anti-idiotype antibodies in cancer patients: Is the modulation of the immune response beneficial for the patient?
AUTOR(ES)
Koprowski, H
RESUMO
Inoculation of human subjects with mouse monoclonal antibody results in the production of anti-idiotype antibody that reacts with the binding site of the monoclonal antibody. This reaction is hapten-inhibited, suggesting that an internal image of the antigen is produced by the anti-idiotype response. The anti-idiotype antibody isolated from sera of three patients showed significant crossreactivity. Patients who developed the anti-idiotype antibody improved clinically and had long remission from their disease. The possible presence of the internal image of cancer antigen on the human immunoglobulin molecule may change the conditions under which the immune system reacts to the tumor antigen and may open new approaches to the control of tumor growth.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=344642Documentos Relacionados
- Anti-idiotype immunization of cancer patients: modulation of the immune response.
- Immune response to the carcinoembryonic antigen in patients treated with an anti-idiotype antibody vaccine.
- Protective anti-idiotype antibodies in the primate model of pyelonephritis.
- Characterization of a monoclonal anti-idiotype antibody to human anti-factor VIII antibodies.
- Characterization of anti-anti-idiotypic antibodies that bind antigen and an anti-idiotype
